(Q40152553)

18 September 2017

title

A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus (English)

1 reference

18 September 2017

hepatitis C virus

1 reference

5

1 reference

18 September 2017

Joseph Torresi

1

0 references

David Jackson

object named as

David C Jackson

9

0 references

author name string

Owen M Stock

2

1 reference

18 September 2017

Alexandra E Fischer

3

1 reference

18 September 2017

Lara Grollo

4

1 reference

18 September 2017

Irene Boo

6

1 reference

18 September 2017

Weiguang Zeng

7

1 reference

18 September 2017

Linda Earnest-Silveira

8

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

45

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

911-920

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

18 September 2017

cites work

1 reference

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

21 January 2018

1 reference

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

21 January 2018

1 reference

The scientific challenge of hepatitis C.

21 January 2018

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses

1 reference

7 January 2021

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells

1 reference

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

1 reference

7 January 2021

Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus

1 reference

7 January 2021

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

1 reference

7 January 2021

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

1 reference

7 January 2021

Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma

1 reference

7 January 2021

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

1 reference

7 January 2021

Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins

1 reference

7 January 2021

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

1 reference

7 January 2021

Analysis of successful immune responses in persons infected with hepatitis C virus

1 reference

7 January 2021

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

1 reference

7 January 2021

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection

1 reference

7 January 2021

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

1 reference

7 January 2021

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

1 reference

7 January 2021

Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus

1 reference

7 January 2021

Neutralizing antibody response during acute and chronic hepatitis C virus infection

1 reference

7 January 2021

Free radical induced polymerization of synthetic peptides into polymeric immunogens

1 reference

7 January 2021

Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines

1 reference

7 January 2021

Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation

1 reference

7 January 2021

Effects on rotavirus cell binding and infection of monomeric and polymeric peptides containing alpha2beta1 and alphaxbeta2 integrin ligand sequences

1 reference

7 January 2021

New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

1 reference

7 January 2021

Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants

1 reference

7 January 2021

Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus

1 reference

7 January 2021

Synthesis of the Mitogenic S-[2,3-Bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide fromEscherichia coliLipoprotein

1 reference

7 January 2021

Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81

1 reference

7 January 2021

Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines

1 reference

7 January 2021

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

7 January 2021

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

1 reference

7 January 2021

Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells

1 reference

7 January 2021

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

1 reference

7 January 2021

Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes

1 reference

7 January 2021

Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses

1 reference

7 January 2021

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization

1 reference

7 January 2021

Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions.

1 reference

7 January 2021

Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?

1 reference

7 January 2021

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

1 reference

7 January 2021

A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry

1 reference

7 January 2021

In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus

1 reference

7 January 2021

A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21538

1 reference

release_wwxjnhq3m5a2thmvzq74cmx23q

18 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wwxjnhq3m5a2thmvzq74cmx23q

24 November 2022

mapped directly with Wikidata item

1 reference